AntiCD25hodot
AntiCD25hodot is a recombinant monoclonal antibody engineered for targeted binding to the CD25 subunit of the interleukin‑2 receptor (IL‑2Rα). The antibody component retains the antigen‑recognition properties of conventional anti‑CD25 targeting agents such as basiliximab or daclizumab, while the additional “hodot” moiety—a hydroxypropyl‑methylcellulose conjugate—provides a biodegradable, hydrophilic polymer coat. This hydrogel-like layer can modulate the immunogenic profile of the antibody and improve its pharmacokinetic properties by reducing rapid clearance and limiting off‑target interactions.
The recombinant construct is expressed in CHO‑K1 cells and purified by protein A affinity chromatography followed
Preclinical studies in mouse models of graft‑versus‑host disease and autoimmune myocarditis have shown that AntiCD25hodot reduces
Currently, the compound is under Phase I clinical evaluation for safety and tolerability in patients undergoing